文献速递哮喘

2026 GINA哮喘策略报告:执行摘要与关键更新

2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes.
PubMed 文献 · Am J Respir Crit Care Med · 2026-10-08

2026 GINA策略报告提供全生命周期哮喘循证管理,核心为基于评估-调整-复查的个体化迭代照护。强调所有患者应接受含ICS治疗,反对单用SABA;成人/青少年首选低剂量ICS-福莫特罗作为抗炎缓解剂。2026关键更新包括扩展AIR选项、修订重症哮喘与生物制剂选择及急性发作管理。

要点

  • 所有哮喘患者均应接受含ICS治疗,不应单用SABA。
  • 成人/青少年首选低剂量ICS-福莫特罗按需或维持加缓解方案。
  • 重症哮喘需核实诊断、优化可调节因素、炎症表型指导生物制剂。

核心结论

  • GINA推荐全生命周期哮喘患者接受含ICS治疗,反对SABA单药治疗。
  • 成人/青少年首选低剂量ICS-福莫特罗作为抗炎缓解剂,可显著减少严重急性发作。

研究设计与样本

  • GINA年度更新的循证策略报告,覆盖哮喘诊断、评估、治疗与预防。
  • 采用评估-调整-复查循环进行个体化迭代照护。

主要发现

  • GINA强烈推荐所有成人、青少年、儿童及大多数学龄前哮喘患者接受含ICS治疗。
  • 与SABA为基础方案相比,低剂量ICS-福莫特罗方案大幅减少严重急性发作且更简便。
  • 儿童年龄特异治疗路径同样强调含ICS治疗与急性发作预防。
  • 重症哮喘管理强调诊断核实、可调节因素优化、炎症表型及生物制剂选择。
  • 2026更新包括扩展AIR选项、修订重症哮喘与生物制剂选择及急性发作管理。

关键数值与推荐

  • GINA推荐反对SABA单药治疗。
  • 成人/青少年Track 1首选低剂量ICS-福莫特罗作为抗炎缓解剂,可按需单用或维持加缓解。
  • 重症哮喘需进行炎症表型分析以指导生物制剂选择,并强调全身糖皮质激素管理。
  • 急性发作护理包括长期预防治疗及出院后管理再评估与行动计划。

临床怎么用

  • 临床应确保所有哮喘患者接受含ICS治疗,避免单用SABA。
  • 成人/青少年优先选用低剂量ICS-福莫特罗作为缓解剂或维持加缓解方案。
  • 定期评估肺功能、吸入技术、依从性、共病及2型生物标志物等风险因素。
  • 重症哮喘应核实诊断、优化可调节因素、进行炎症表型分型后选择生物制剂。
  • 急性发作后应重新评估管理并制定行动计划,纳入长期预防治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Global Initiative for Asthma (GINA) Strategy Report provides a comprehensive, annually updated evidence-based approach to asthma diagnosis, assessment, treatment, and prevention across the lifespan. Its central approach is personalized, iterative care based on the Assess-Adjust-Review cycle for both symptom control and reduction of future risk (including severe exacerbations, persistent airflow limitation, and treatment-related harm). GINA emphasizes objective confirmation of diagnosis wherever possible, and regular assessment of lung function, inhaler technique, adherence, multimorbidity, risk factors (including Type-2 biomarkers), and patient goals and preferences. GINA strongly recommends that all adults, adolescents, children and most preschoolers with asthma should receive inhaled corticosteroid (ICS)-containing treatment. GINA recommends against short-acting beta2-agonist (SABA)-only treatment. For adults/adolescents, GINA Track 1 using low-dose ICS-formoterol, an anti-inflammatory reliever (AIR), either as-needed-only (AIR-only) or as maintenance-and-reliever therapy (MART), is preferred because of its substantial reduction in severe exacerbations compared with SABA-based regimens, and its simplicity. Age-specific treatment pathways in children also emphasize ICS-containing therapy and exacerbation prevention. For difficult-to-treat and severe asthma, GINA provides structured guidance, emphasizing diagnostic verification, optimization of modifiable factors, inflammatory phenotyping, biologic therapy selection, and (as for all patients) systemic corticosteroid stewardship. Acute exacerbation care incorporates long-term preventive treatment, including post-discharge reassessment of management and action plan. Key 2026 updates include expanded AIR options for adults and children, revised guidance on severe asthma and selection of biologic treatment, and substantial updates to acute asthma management. GINA integrates evidence-based management with shared decision-making, self-management education, implementation, and global advocacy to reduce preventable asthma morbidity and mortality.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Reddel HK, Allan K, Bacharier LB, et al. 2026 Global Initiative for Asthma (GINA) Strategy Report: Executive Summary and Key Changes. Am J Respir Crit Care Med. 2026. PMID: 42847657. doi:10.1093/ajrccm/aamag542

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。